Highlights Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.34 ^USD	+0.75%		-1.47%	+8.06%

Apr. 23	Averoa Seeks EU Approval for Chronic Kidney Disease Drug	MT
Apr. 16	Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Averoa Seeks EU Approval for Chronic Kidney Disease Drug	Apr. 23	MT
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	Apr. 16	CI
Akebia Shares Rally Premarket After FDA Approves Vafseo	Mar. 28	DJ
U.S. FDA approves Akebia's anemia drug	Mar. 27	RE
U.S. FDA approves Akebia's anemia drug	Mar. 27	RE
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	Mar. 27	CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M	Mar. 14	MT
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Mar. 14	CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q3 Revenue $42M	Nov. 08	MT
Akebia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Akebia Therapeutics Says FDA Accepts Vadadustat Resubmission	23-10-25	MT
Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023	23-10-18	CI
Akebia Therapeutics Resubmits New Drug Application to US FDA for Vadadustat	23-09-28	MT
Akebia Therapeutics Says Australia Approves Anemia Oral Drug Vafseo	23-09-26	MT
Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023	23-09-26	CI
Akebia Therapeutics, Inc. Announces Approval of Vafseo® in Australia	23-09-26	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q2 Revenue $56.4M	23-08-25	MT
Akebia Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Highlights

Filters